hotspot -WSS

hotspot

author：explore 2025-09-30 18:17:25 - browse：96846

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： WHO calls for emergency meeting on new China virus, as cases spread

WSS

Medicare to cover more brain scans for Alzheimer’s patients

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Supreme Court mifepristone arguments center on docs' right to sue

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Readout Newsletter: Merck, Vertex, and Viking updates

hotspot

hotspot

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Continuity nursing helped my family in our darkest PICU moments

Custom gene therapy hints at new path for rare disease treatments

Moonlake's readout produced a cash windfall. Risks remain

Food as medicine: Medically tailored meals may get standardized

New air purifier tech could be key to improving indoor air quality

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Wikipedia

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Sanofi seeks simpler, safer CRISPR sickle cell cure

Vertex Pharmaceuticals may move headquarters in Boston

Startup Neumora takes a novel depression drug to Phase 3

Listen: Wegovy in the brain & pivotal Alzheimer's data

hotspot

leisure time

explore

knowledge